Disease Analysis: Non-Small Cell Lung Cancer (NSCLC)
Author: Tara Hansen
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Disease Overview
Lung cancer is generally categorized as either small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). Of these, NSCLC is the most common type of lung cancer, accounting for roughly 85% of all cases. NSCLC can be further divided into non-squamous and squamous NSCLC histologies. Squamous NSCLC refers to patients with squamous cell carcinoma, whereas non-squamous NSCLC includes patients with adenocarcinoma, large cell carcinoma, and other less common subtypes. Incidence of adenocarcinoma and squamous cell carcinoma varies greatly by both geographic region and gender. In general, adenocarcinoma comprises approximately 30–50% of all lung cancer cases, while squamous cell carcinoma accounts for roughly 25–35%.
Latest key takeaways
- Datamonitor Healthcare estimates that in 2018, there were 1.8 million incident cases of non-small cell lung cancer (NSCLC) worldwide, and expects that number to increase to 1.9 million incident cases by 2027. The majority of NSCLC diagnoses (65.4%) worldwide are in males, ranging from 52.9% to 72.1% across regions.
- In the last three years, the number of therapies targeting specific sensitizing mutations in metastatic NSCLC has drastically increased, permanently altering the treatment landscape. Many of the new drugs have shown dramatically increased response rates over the previous standard-of-care therapies. However, given the relatively small percentage of metastatic NSCLC patients presenting with each oncogenic driver, competition is fierce and first-to-market advantage is critical.
- Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1)-targeted monoclonal antibodies for NSCLC are forecast to remain the best-selling class of drugs for this indication. Keytruda was the first PD-1/PD-L1 inhibitor to gain regulatory approval for first-line NSCLC patients without an oncogenic driver and has risen to dominance in this market as label expansions have broadened its target patient population and as late-phase trials have revealed consistently positive data. Furthermore, the commercial potential of this class of drugs will increase over the forecast period as the use of checkpoint inhibitors will likely soon extend beyond the metastatic patient population. Label expansions into the earlier treatment settings may provide an opportunity for the other checkpoint inhibitors to differentiate themselves from Keytruda and carve out a niche in this lucrative market.
- PD-L1 inhibitor Imfinzi’s approval for sequential therapy of locally advanced patients following chemoradiation minimizes direct competition with established immunotherapies and has allowed the drug to secure a modest market share.
- Third-generation EGFR inhibitor Tagrisso is now the first-line standard-of-care treatment for NSCLC patients whose tumors harbor activating EGFR mutations (exon 19 deletion or L858R point mutation). Despite competition from Tarceva, Iressa, Gilotrif, Vizimpro, and Alunbrig, Tagrisso will continue to dominate the EGFR inhibitor market due to continued uptake and a recent label expansion into the adjuvant setting. However, Janssen’s recently initiated Phase III MARIPOSA study of amivantamab in combination with lazertinib is the first head-to-head trial against Tagrisso, and the combination could eventually threaten Tagrisso’s position in the first-line setting.
- Amivantamab and mobocertinib are currently in late-stage development for metastatic NSCLC patients whose tumors harbor an exon 20 insertion mutation in EGFR, a population of patients where currently approved therapies are not effective. Competition will be fierce between these two drugs, and the first therapy to market will likely dominate. However, the relative rarity of this mutation limits the commercial potential of an approval in this patient population, and both therapies are also in development for the treatment of other actionable mutations.
- Alecensa has become the new first-line standard of care for ALK rearrangement-positive NSCLC. The Phase III ALEX study demonstrated superior progression-free survival when treated with Alecensa compared with previous standard of care Xalkori. Alecensa will likely remain the class leader even though it will face competition in the first-line setting from other ALK inhibitors such as Zykadia, Alunbrig, and Lorbrena. Dual ALK/ROS1 inhibitor Lorbrena is also approved in both the first- and second-line settings, but has experienced only modest uptake thus far.
- The ALK inhibitors Rozlytrek and Xalkori are both approved for the treatment of metastatic NSCLC patients whose tumors have a ROS1 rearrangement or fusion. Rozlytrek is also approved as a monotherapy for patients with NTRK+ gene fusions. The combined data from Rozlytrek’s development program compare favorably to the data for Xalkori, particularly in patients with CNS metastases at baseline. ROS1 gene rearrangements are present in 1–2% of NSCLC patients, while NTRK fusions are present in approximately 0.2% of cases.
- The combination of BRAF inhibitor Tafinlar and MEK inhibitor Mekinist has become the standard of care for advanced or metastatic NSCLC with BRAF V600E mutations. However, only 1–2% of NSCLC patients have a BRAF V600E mutation, which limits the combination’s commercial potential.
- Two MET inhibitors, Tabrecta and Tepmetko, have been approved for NSCLC patients with a MET exon 14 skipping mutation in the US and Japan. Both drugs are also in development for MET-amplified NSCLC and for patients with EGFR-mutated, c-MET-amplified NSCLC who have progressed after EGFR inhibitor treatment. Potential label expansions into these treatment settings represent a noteworthy market opportunity. Approximately 1–4% of NSCLC patients have a MET exon 14 skipping mutation.
- Retevmo is the first drug approved for the treatment of patients with RET fusion-positive NSCLC. In the pivotal Phase I/II trial, Retevmo demonstrated efficacy in RET fusion-positive patients and in a subgroup of patients with brain metastases. The confirmatory Phase III LIBRETTO-431 trial is ongoing, and approvals in both Europe and Japan are expected based on the Phase I/II data. However, Retevmo will face competition from RET inhibitor Gavreto, which was recently approved in the US.
- As therapies targeting specific oncogenic drivers have established themselves in metastatic NSCLC, attention has shifted toward mutations that do not yet have targeted therapies. Two notable pipeline examples are KRAS inhibitors sotorasib and adagrasib. Both KRAS inhibitors are being investigated as second-line or later treatments for patients with KRAS G12C-mutant NSCLC, a patient population that was previously thought to be undruggable. This is a significant market opportunity given that approximately 13% of NSCLC patients have KRAS p.G12C mutations.
- As checkpoint inhibitor regimens dominate in the first-line setting for patients without sensitizing mutations, effective treatments for the post-immunotherapy setting remain the largest unmet need within the indication. Treatment for these patients is largely palliative, and patients currently have very limited treatment options. A number of therapies, including Cabometyx, Lenvima, sitravatinib, and tusamitamab ravtansine, are in development for this treatment setting.
- The overall likelihood of approval of a Phase I NSCLC asset is 8.1%, and the average probability a drug advances from Phase III is 37.2%. NSCLC drugs, on average, take 9.1 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
- Key upcoming catalysts for 2021 include top-line results for the Phase III SAPPHIRE study of sitravatinib and Opdivo and the Phase III JAVELIN Lung 100 study of Bavencio, as well as PDUFA dates for amivantamab and adagrasib.
CONTENTS
11 OVERVIEW
11 Latest key takeaways
13 DISEASE BACKGROUND
13 Definition
13 Risk factors
14 Symptoms
15 Screening
15 Diagnosis
15 Prognosis
16 Patient segmentation
18 TREATMENT
18 Early-stage NSCLC (Stage I–II; all subtypes)
18 Advanced NSCLC (Stage IIIa–IIIc; all subtypes)
18 Metastatic NSCLC – molecular profiling
19 Metastatic NSCLC: EGFR+
20 Metastatic NSCLC: EGFR+, second line
21 Metastatic NSCLC: ALK+
22 Metastatic NSCLC: ROS1+
23 Metastatic NSCLC: BRAF V600E mutation
24 Metastatic NSCLC: MET exon 14 skipping
25 Metastatic NSCLC: RET+
26 Metastatic NSCLC: NTRK+
27 Metastatic NSCLC: PD-L1+ (≥50%)
28 Metastatic NSCLC: PD-L1+ (≥1–49%)
29 Metastatic NSCLC: all other
30 Metastatic NSCLC: maintenance therapy
31 Metastatic NSCLC: all other second line or later
32 EPIDEMIOLOGY
32 Incidence methodology
35 Prevalence of common non-small cell lung cancer biomarkers
37 MARKETED DRUGS
46 PIPELINE DRUGS
69 KEY REGULATORY EVENTS
69 Latecomer Libtayo Wins Coveted First-Line NSCLC Monotherapy Indication
69 Five New EU Filings Leave Starting Blocks At EMA
69 EMD Serono’s Tepmetko Is 6th Novel RTOR Approval
69 Takeda’s Alunbrig For NSCLC
70 World-First Nod For Yuhan’s Lung Cancer Drug, In Korea
70 AstraZeneca On Tagrisso’s Milestone Advance Into Adjuvant Lung Cancer
70 Tepotinib Among Latest EU Filings
70 Lilly’s Multi-Tumor Treatment Retsevmo Closer To EU Approval
71 Keeping Track: J&J Amivantamab Submitted
71 Oncology, Rare Disease Drugs Dominate New China Approvals
71 Imfinzi Gains Four-Week, Fixed-Dose Regimen
71 Real-Time Oncology Review Welcomes Lorbrena
72 Routine UK Funding OKd For Tagrisso In First & Second-Line NSCLC
72 FDA OKs Blueprint/Roche’s Gavreto As Rival To Lilly’s Retevmo
72 FDA Approves Guardant’s Guardant360 CDX Comprehensive Genomic Profile
72 AZ’s ‘Practice Changing’ ADAURA Trial Earns Tagrisso’s Third BTD
73 Japan Nods Include Global Firsts For Duvroq, Vafseo And First Local Biosimilar Humira
73 English Funding Success For Roche’s Rozlytrek In NSCLC
73 Roche’s Tecentriq Notches Approval For First-Line NSCLC Monotherapy
73 Bristol Wins First Of Two Important Opdivo/Yervoy First-Line NSCLC Approvals
74 US FDA Dismisses Post-Progression Endpoint In Cyramza Lung Cancer Study
75 PROBABILITY OF SUCCESS
76 LICENSING AND ASSET ACQUISITION DEALS
76 TRIGR, Elpiscience Partner On Cancer Immunotherapy In China
76 Bayer Enters CAR-T Space With Atara Pact
76 Merck Pays $2.75bn To Access VelosBio’s ROR1-Targeting ADCs
76 AnHeart Acquires Two More Oncology Assets From Daiichi
77 AZ Bets Big On ADCs As It Inks Second, $6bn Deal With Daiichi
77 Roche Backs Blueprint’s Precision Therapy Pralsetinib To Challenge Lilly
77 Guardant Will Collaborate With Janssen On Lung Cancer Companion Diagnostic
78 CLINICAL TRIAL LANDSCAPE
79 Sponsors by status
80 Sponsors by phase
81 Recent events
87 DRUG ASSESSMENT MODEL
87 EGFR inhibitors
89 ROS1 and NTRK gene fusions
89 ALK inhibitors
90 KRAS inhibitors
91 RET inhibitors
91 BRAF inhibitors
92 PARP inhibitors
92 MET inhibitors
93 PD-1/PD-L1 inhibitors
94 TIGIT inhibitor
95 Interleukin 1b antagonist
95 Microtubule inhibitors
95 Folate analog metabolic inhibitor
96 VEGF inhibitors
96 Post-immunotherapy
98 MARKET DYNAMICS
99 FUTURE TRENDS
99 Keytruda is forecast to remain the leading immunotherapy approved for NSCLC
99 Checkpoint inhibitors are expected to move into earlier stages of NSCLC
100 Approvals and subsequent uptake for new therapies in the post-immunotherapy setting will contribute significantly to growth in the NSCLC market
100 Alecensa is expected to continue leading the ALK inhibitor class due to strong results in the first-line setting, despite potential competition
101 Tagrisso will remain the best-selling EGFR inhibitor due to continued uptake in the first-line setting and a label expansion into the adjuvant setting
101 New EGFR inhibitors will address the EGFR exon 20 insertion mutation, which is associated with poor response to current treatments
102 The approval and uptake of MET inhibitors is expected to address unmet needs in patients with exon 14 skipping mutations
102 Recent approvals and subsequent uptake of therapies targeting new mutational drivers will support growth in the NSCLC market over the forecast period
102 Generic or biosimilar erosion of key brands will have minimal impact on growth
104 CONSENSUS FORECASTS
109 RECENT EVENTS AND ANALYST OPINION
109 Tecentriq for NSCLC (March 21, 2021)
110 Ilaris for NSCLC (March 9, 2021)
111 Keytruda for NSCLC (January 29, 2021)
112 Repotrectinib for NSCLC (January 29, 2021)
114 AMG 510 for NSCLC (January 28, 2021)
116 Amivantamab for NSCLC (January 28, 2021)
118 TAK-788 for NSCLC (January 28, 2021)
120 Bintrafusp Alfa for NSCLC (January 19, 2021)
121 Poziotinib for NSCLC (December 22, 2020)
123 Keytruda for NSCLC (November 9, 2020)
124 Nerlynx for NSCLC (November 5, 2020)
126 Vopratelimab for NSCLC (November 2, 2020)
128 MRTX849 for NSCLC (October 25, 2020)
129 MK-1308 for NSCLC (October 16, 2020)
130 Opdivo for NSCLC (October 7, 2020)
132 AMG 510 for NSCLC (October 5, 2020)
133 Keytruda for NSCLC (September 21, 2020)
134 Libtayo for NSCLC (September 21, 2020)
136 AMG 510 for NSCLC (September 20, 2020)
138 Amivantamab for NSCLC (September 20, 2020)
139 Lorbrena for NSCLC (September 19, 2020)
141 Tagrisso for NSCLC (September 19, 2020)
143 U3-1402 for NSCLC (September 18, 2020)
145 CLN-081 for NSCLC (September 17, 2020)
146 Lenvima for NSCLC (September 17, 2020)
147 Repotrectinib for NSCLC (August 19, 2020)
149 Ensartinib for NSCLC (August 8, 2020)
150 Lorbrena for NSCLC (August 5, 2020)
151 Opdivo for NSCLC (August 3, 2020)
153 Poziotinib for NSCLC (July 27, 2020)
154 SAR408701 for NSCLC (May 31, 2020)
156 Tagrisso for NSCLC (May 31, 2020)
158 Enhertu for NSCLC (May 29, 2020)
160 Opdivo for NSCLC (May 29, 2020)
161 Sym015 for NSCLC (May 29, 2020)
163 Tagrisso for NSCLC (May 29, 2020)
164 Tepmetko for NSCLC (May 29, 2020)
166 Tabrecta for NSCLC (May 14, 2020)
168 Enhertu for NSCLC (May 13, 2020)
170 Opdivo for NSCLC (May 13, 2020)
172 Tagrisso for NSCLC (May 13, 2020)
174 Tiragolumab for NSCLC (May 13, 2020)
175 Libtayo for NSCLC (April 27, 2020)
177 Tagrisso for NSCLC (April 10, 2020)
178 Tedopi for NSCLC (April 1, 2020)
181 KEY UPCOMING EVENTS
184 KEY OPINION LEADER INSIGHTS
185 UNMET NEEDS
186 BIBLIOGRAPHY
188 Prescription information
190 APPENDIX
LIST OF FIGURES
34 Figure 1: Trends in incident cases of NSCLC, 2018–27
46 Figure 2: Overview of pipeline drugs for NSCLC in the US
46 Figure 3: Pipeline drugs for NSCLC, by company
47 Figure 4: Pipeline drugs for NSCLC, by drug type
47 Figure 5: Pipeline drugs for NSCLC, by classification
75 Figure 6: Probability of success in the NSCLC pipeline
78 Figure 7: Clinical trials in NSCLC
78 Figure 8: Top 10 drugs for clinical trials in NSCLC
79 Figure 9: Top 10 companies for clinical trials in NSCLC
79 Figure 10: Trial locations in NSCLC
80 Figure 11: NSCLC trials status
81 Figure 12: NSCLC trials sponsors, by phase
87 Figure 13: Datamonitor Healthcare’s drug assessment summary for NSCLC
98 Figure 14: Market dynamics in NSCLC
99 Figure 15: Future trends in NSCLC
111 Figure 16: Ilaris for NSCLC (March 9, 2021): Phase III – CANOPY-2
112 Figure 17: Keytruda for NSCLC (January 29, 2021): Phase III – KEYNOTE-598
114 Figure 18: Repotrectinib for NSCLC (January 29, 2021): Phase I/II – TRIDENT-1
116 Figure 19: AMG 510 for NSCLC (January 28, 2021): Phase I/II – CodeBreaK 100
118 Figure 20: Amivantamab for NSCLC (January 28, 2021): Phase I – CHRYSALIS (Advanced NSCLC)
120 Figure 21: TAK-788 for NSCLC (January 28, 2021): Phase I/II – EXCLAIM
123 Figure 22: Poziotinib for NSCLC (December 22, 2020): Phase II – ZENITH20 (EGFR or HER2 Exon 20 Mut.)
126 Figure 23: Nerlynx for NSCLC (November 5, 2020): Phase II – SUMMIT Basket (HER2mut, EGFRmut)
128 Figure 24: Vopratelimab for NSCLC (November 2, 2020): Phase II – EMERGE (w/Ipilimumab)
130 Figure 25: MK-1308 for NSCLC (October 16, 2020): Phase I/II – w/Pembrolizumab
132 Figure 26: Opdivo for NSCLC (October 7, 2020): Phase III – CheckMate-816
134 Figure 27: Keytruda for NSCLC (September 21, 2020): Phase III – KEYNOTE-024 (1L Monotherapy)
136 Figure 28: Libtayo for NSCLC (September 21, 2020): Phase III – EMPOWER-Lung 1 (1st Line)
138 Figure 29: AMG 510 for NSCLC (September 20, 2020): Phase I/II – CodeBreaK 100
141 Figure 30: Lorbrena for NSCLC (September 19, 2020): Phase III – CROWN (vs. Crizotinib)
143 Figure 31: Tagrisso for NSCLC (September 19, 2020): Phase III – ADAURA
145 Figure 32: U3-1402 for NSCLC (September 18, 2020): Phase I – A-U102
149 Figure 33: Repotrectinib for NSCLC (August 19, 2020): Phase I/II – TRIDENT-1
151 Figure 34: Lorbrena for NSCLC (August 5, 2020): Phase III – CROWN (vs. Crizotinib)
153 Figure 35: Opdivo for NSCLC (August 3, 2020): Phase III – TASUKI-52
154 Figure 36: Poziotinib for NSCLC (July 27, 2020): Phase II – ZENITH20 (EGFR or HER2 Exon 20 Mut.)
156 Figure 37: SAR408701 for NSCLC (May 31, 2020): Phase I/II – Advanced Solid Tumors
158 Figure 38: Tagrisso for NSCLC (May 31, 2020): Phase III – ADAURA
160 Figure 39: Enhertu for NSCLC (May 29, 2020): Phase II – DESTINY-Lung01
163 Figure 40: Sym015 NSCLC (May 29, 2020): Phase I/II – Safety (Anti-MET)
166 Figure 41: Tepmetko for NSCLC (May 29, 2020): Phase II – VISION (Adenocarcinoma)
168 Figure 42: Tabrecta for NSCLC (May 14, 2020): Phase II – GEOMETRY mono-1
170 Figure 43: Enhertu for NSCLC (May 13, 2020): Phase II – DESTINY-Lung01
172 Figure 44: Opdivo for NSCLC (May 13, 2020): Phase III – CheckMate-9LA (Stage IV, w/Ipilimumab)
174 Figure 45: Tagrisso for NSCLC (May 13, 2020): Phase III – ADAURA
177 Figure 46: Libtayo for NSCLC (April 27, 2020): Phase III – EMPOWER-Lung 1 (1st Line)
180 Figure 47: Tedopi for NSCLC (April 1, 2020): Phase III – ATALANTE-1
181 Figure 48: Key upcoming events in NSCLC (1 of 4)
182 Figure 49: Key upcoming events in NSCLC (2 of 4)
182 Figure 50: Key upcoming events in NSCLC (3 of 4)
183 Figure 51: Key upcoming events in NSCLC (4 of 4)
LIST OF TABLES
16 Table 1: Five-year survival rates of lung cancer, by stage at diagnosis
17 Table 2: Non-small cell lung cancer staging and corresponding TNM classifications
20 Table 3: Preferred branded first-line treatment regimens for patients with Stage IV EGFR+ NSCLC
21 Table 4: Preferred branded treatment regimens for patients who progress on first- and second-generation EGFR TKIs
22 Table 5: Preferred branded first- and second-line treatment regimens for patients with Stage IV ALK+ NSCLC
23 Table 6: Preferred treatment regimens for patients with Stage IV ROS1+ NSCLC
24 Table 7: Preferred treatment regimens for patients with Stage IV BRAF V600E mutated NSCLC
25 Table 8: Preferred treatment regimens for patients with Stage IV NSCLC and a MET exon 14 skipping mutation
26 Table 9: Preferred treatment regimens for patients with Stage IV RET+ NSCLC
27 Table 10: Preferred treatment regimens for patients with Stage IV NTRK+ NSCLC
28 Table 11: Preferred branded first-line treatment regimens for patients with advanced NSCLC and PD-L1+ TPS ≥50%
29 Table 12: Preferred branded first-line treatment regimens for patients with advanced NSCLC and PD-L1+ TPS ≥1–49%
30 Table 13: Preferred branded first-line treatment regimens for patients with advanced NSCLC
31 Table 14: Preferred branded second-line or later treatment regimens for patients with metastatic NSCLC
33 Table 15: Incident cases of NSCLC, 2018–27
35 Table 16: Incident cases of NSCLC, by gender, 2018
38 Table 17: Marketed drugs for NSCLC
48 Table 18: Pipeline drugs for NSCLC in the US
105 Table 19: Historical global sales, by drug ($m), 2015–19
107 Table 20: Forecasted global sales, by drug ($m), 2021–25
109 Table 21: Tecentriq for NSCLC (March 21, 2021)
110 Table 22: Ilaris for NSCLC (March 9, 2021)
111 Table 23: Keytruda for NSCLC (January 29, 2021)
113 Table 24: Repotrectinib for NSCLC (January 29, 2021)
114 Table 25: AMG 510 for NSCLC (January 28, 2021)
117 Table 26: Amivantamab for NSCLC (January 28, 2021)
119 Table 27: TAK-788 for NSCLC (January 28, 2021)
121 Table 28: Bintrafusp Alfa for NSCLC (January 19, 2021)
122 Table 29: Poziotinib for NSCLC (December 22, 2020)
124 Table 30: Keytruda for NSCLC (November 9, 2020)
125 Table 31: Nerlynx for NSCLC (November 5, 2020)
127 Table 32: Vopratelimab for NSCLC (November 2, 2020)
128 Table 33: MRTX849 for NSCLC (October 25, 2020)
129 Table 34: MK-1308 for NSCLC (October 16, 2020)
131 Table 35: Opdivo for NSCLC (October 7, 2020)
132 Table 36: AMG 510 for NSCLC (October 5, 2020)
133 Table 37: Keytruda for NSCLC (September 21, 2020)
135 Table 38: Libtayo for NSCLC (September 21, 2020)
137 Table 39: AMG 510 for NSCLC (September 20, 2020)
139 Table 40: Amivantamab for NSCLC (September 20, 2020)
140 Table 41: Lorbrena for NSCLC (September 19, 2020)
142 Table 42: Tagrisso for NSCLC (September 19, 2020)
144 Table 43: U3-1402 for NSCLC (September 18, 2020)
146 Table 44: CLN-081 for NSCLC (September 17, 2020)
147 Table 45: Lenvima for NSCLC (September 17, 2020)
148 Table 46: Repotrectinib for NSCLC (August 19, 2020)
149 Table 47: Ensartinib for NSCLC (August 8, 2020)
150 Table 48: Lorbrena for NSCLC (August 5, 2020)
152 Table 49: Opdivo for NSCLC (August 3, 2020)
153 Table 50: Poziotinib for NSCLC (July 27, 2020)
155 Table 51: SAR408701 for NSCLC (May 31, 2020)
157 Table 52: Tagrisso for NSCLC (May 31, 2020)
159 Table 53: Enhertu for NSCLC (May 29, 2020)
161 Table 54: Opdivo for NSCLC (May 29, 2020)
162 Table 55: Sym015 for NSCLC (May 29, 2020)
163 Table 56: Tagrisso for NSCLC (May 29, 2020)
164 Table 57: Tepmetko for NSCLC (May 29, 2020)
167 Table 58: Tabrecta for NSCLC (May 14, 2020)
169 Table 59: Enhertu for NSCLC (May 13, 2020)
171 Table 60: Opdivo for NSCLC (May 13, 2020)
172 Table 61: Tagrisso for NSCLC (May 13, 2020)
175 Table 62: Tiragolumab for NSCLC (May 13, 2020)
176 Table 63: Libtayo for NSCLC (April 27, 2020)
177 Table 64: Tagrisso for NSCLC (April 10, 2020)
179 Table 65: Tedopi for NSCLC (April 1, 2020)
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: Acute Myeloid Leukemia (AML) 
Sign up to the